基本情報
- 標準SMILES
CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3.Cl- InChIKey
SKYZYDSNJIOXRL-BTQNPOSSSA-N- 分子式
- C17H18ClNO2
- 平均分子量
- 303.8 g/mol
- 単同位体質量
- 303.1026065
名称と識別子
- 優先名称
- 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-
- IUPAC
- (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride
- 現地名
- (-)-アポモルフィン·塩酸塩
- 英語名
- Apomorphine hydrochloride
- 分子式
- C17H18ClNO2
- 分子量
- 303.78
名称と別名
名称をさらに表示
データベース識別子
- CAS
314-19-2- PubChem CID
- 9410
- DTXSID
DTXSID5040598- UNII
- 9K13MD7A0D
物性
構造計算による物性
- 極性表面積
- 43.7 Ų
- 水素結合供与体数
- 3
- 水素結合受容体数
- 3
- 回転可能結合数
- 0
- 重原子数
- 21
- 形式電荷
- 0
- 複雑度
- 374
実験および物理化学的性質
物理化学的性質
- 融点
- 250 ℃ · >250℃
- 貯蔵温度
- Store at RT
- 溶解性
- 1.08 mg/mL · ≥1.08 mg/mL in EtOH with ultrasonic; ≥12.9 mg/mL in DMSO; ≥5.12 mg/mL in H2O
- 外見
- solid
- EPAの化学物質情報
- Apomorphine hydrochloride (314-19-2)
安全と法規制
危険有害性情報
Other Safety Information
IMAP assessments - 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)-: Environment tier I assessment;IMAP assessments - 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)-: Human health tier I assessment
安全データ
- tsca
- TSCA listed
- ridadr
- 3249
- 毒性
- mmo-sat 20 mg/plate MUREAV 137,17,84
- hazard_class
- 6.1(b)
- packing_group
- III
化学と産業
用途と製造
応用分野
使用Emetic.
一般的な説明Apomorphine hydrochloride,(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolone-10,11-diol hydrochloride (Apokyn), is awhite or off-white powder or crystal soluble in hot water(pKa=8.92). Apormorphine is an aporphine alkaloid of thebenzoquinoline class. Oral apomorphine is poorly absorbedand has a bioavailability of less than 4%. Upon subcutaneousadministration, apomorphine is completely absorbed. Within10 to 20 minutes, the maximum concentration of the drug isdistributed from the blood plasma to the CSF. Other potentialroutes of administration include continuous subcutaneous infusion,intravenous infusion, intranasal spray application,sublingual, and rectal administration.23 The agent is highlylipophilic in nature, allowing for rapid diffusion across theBBB after injection. Apomorphine has a short plasma halflife;however, clinical effects may last from 60 to 90 minutes.Apomorphine displays a significant degree of interpatientvariability in its pharmacokinetic profile. Studies of bothintravenous and subcutaneous injection routes found this variation was not attributable to body weight, age, gender,and duration of PD or L-DOPA dose/duration alone.Apomorphine is extensively metabolized. Hypothesizedroutes include sulfation, N-demethylation, glucuronidation,and oxidation. Subcutaneous injections of apomorphine arerenally and hepatically cleared, with the majority appearingto be renally cleared. Dosage adjustments are needed in bothliver and renal impairment. The activity of apomorphine isbelieved to be caused by stimulation of postsynaptic D1- andD2-type receptors within the caudate/putamen in the brain.Apomorphine is indicated for the acute, intermittent treatmentof hypomobility, “off” episodes (“end-of-dose wearingoff” and unpredictable on/off episodes) associated with advancedPD.
上流・下流製品情報
上流原料
サプライヤー17 社
関連反応
関連ノート
読み込み中…